Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy

Yanru Wang, Shumin Zhang, Shareen Iqbal, Zhengjia Chen, Xiaojing Wang, Yongqiang A. Wang, David Liu, Kevin Bai, Chad Ritenour, Omer Kucuk, Daqing Wu

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Docetaxel treatment is the only first-line chemotherapy with a survival benefit in metastatic castration-resistant prostate cancer (PCa). Nonetheless, most patients become docetaxel resistant and inevitably progress with no cure. In this study, we investigated the potential of pomegranate extract (PE) in targeting metastatic castration-resistant PCa and improving docetaxel chemotherapy. METHODS The in vitro and in vivo effect of POMx, a PE formula currently approved for clinical trials, in metastatic castration-resistant PCa cells was evaluated in experimental models. RESULTS We demonstrated that POMx exhibited potent in vitro cytotoxicity in metastatic castration-resistant PCa cells. Mechanistic studies identified survivin as a novel molecular target that may mediate the anti-cancer activity of POMx, presumably through the inhibition of signal transducer and activator of transcription 3. The in vivo administration of POMx treatment effectively inhibited survivin, induced apoptosis, retarded C4-2 tumor growth in skeleton and significantly enhanced the efficacy of docetaxel in athymic nude mice. CONCLUSION These results provide the first preclinical evidence that POMx may be effective in treating metastatic castration-resistant PCa and enhancing the efficacy of docetaxel chemotherapy. Prostate 74:497-508, 2014.

Original languageEnglish (US)
Pages (from-to)497-508
Number of pages12
JournalProstate
Volume74
Issue number5
DOIs
StatePublished - May 1 2014
Externally publishedYes

Fingerprint

docetaxel
Punicaceae
Castration
Bone Development
Prostatic Neoplasms
Drug Therapy
Nude Mice
STAT3 Transcription Factor
Skeleton
Prostate
Neoplasms
Theoretical Models
Clinical Trials
Apoptosis
Survival

Keywords

  • animal model
  • bone metastasis
  • docetaxel
  • pomegranate extract
  • prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy. / Wang, Yanru; Zhang, Shumin; Iqbal, Shareen; Chen, Zhengjia; Wang, Xiaojing; Wang, Yongqiang A.; Liu, David; Bai, Kevin; Ritenour, Chad; Kucuk, Omer; Wu, Daqing.

In: Prostate, Vol. 74, No. 5, 01.05.2014, p. 497-508.

Research output: Contribution to journalArticle

Wang, Y, Zhang, S, Iqbal, S, Chen, Z, Wang, X, Wang, YA, Liu, D, Bai, K, Ritenour, C, Kucuk, O & Wu, D 2014, 'Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy', Prostate, vol. 74, no. 5, pp. 497-508. https://doi.org/10.1002/pros.22769
Wang, Yanru ; Zhang, Shumin ; Iqbal, Shareen ; Chen, Zhengjia ; Wang, Xiaojing ; Wang, Yongqiang A. ; Liu, David ; Bai, Kevin ; Ritenour, Chad ; Kucuk, Omer ; Wu, Daqing. / Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy. In: Prostate. 2014 ; Vol. 74, No. 5. pp. 497-508.
@article{631f02ae8d27489fbcacc1065be37559,
title = "Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy",
abstract = "Docetaxel treatment is the only first-line chemotherapy with a survival benefit in metastatic castration-resistant prostate cancer (PCa). Nonetheless, most patients become docetaxel resistant and inevitably progress with no cure. In this study, we investigated the potential of pomegranate extract (PE) in targeting metastatic castration-resistant PCa and improving docetaxel chemotherapy. METHODS The in vitro and in vivo effect of POMx, a PE formula currently approved for clinical trials, in metastatic castration-resistant PCa cells was evaluated in experimental models. RESULTS We demonstrated that POMx exhibited potent in vitro cytotoxicity in metastatic castration-resistant PCa cells. Mechanistic studies identified survivin as a novel molecular target that may mediate the anti-cancer activity of POMx, presumably through the inhibition of signal transducer and activator of transcription 3. The in vivo administration of POMx treatment effectively inhibited survivin, induced apoptosis, retarded C4-2 tumor growth in skeleton and significantly enhanced the efficacy of docetaxel in athymic nude mice. CONCLUSION These results provide the first preclinical evidence that POMx may be effective in treating metastatic castration-resistant PCa and enhancing the efficacy of docetaxel chemotherapy. Prostate 74:497-508, 2014.",
keywords = "animal model, bone metastasis, docetaxel, pomegranate extract, prostate cancer",
author = "Yanru Wang and Shumin Zhang and Shareen Iqbal and Zhengjia Chen and Xiaojing Wang and Wang, {Yongqiang A.} and David Liu and Kevin Bai and Chad Ritenour and Omer Kucuk and Daqing Wu",
year = "2014",
month = "5",
day = "1",
doi = "10.1002/pros.22769",
language = "English (US)",
volume = "74",
pages = "497--508",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "5",

}

TY - JOUR

T1 - Pomegranate extract inhibits the bone metastatic growth of human prostate cancer cells and enhances the in vivo efficacy of docetaxel chemotherapy

AU - Wang, Yanru

AU - Zhang, Shumin

AU - Iqbal, Shareen

AU - Chen, Zhengjia

AU - Wang, Xiaojing

AU - Wang, Yongqiang A.

AU - Liu, David

AU - Bai, Kevin

AU - Ritenour, Chad

AU - Kucuk, Omer

AU - Wu, Daqing

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Docetaxel treatment is the only first-line chemotherapy with a survival benefit in metastatic castration-resistant prostate cancer (PCa). Nonetheless, most patients become docetaxel resistant and inevitably progress with no cure. In this study, we investigated the potential of pomegranate extract (PE) in targeting metastatic castration-resistant PCa and improving docetaxel chemotherapy. METHODS The in vitro and in vivo effect of POMx, a PE formula currently approved for clinical trials, in metastatic castration-resistant PCa cells was evaluated in experimental models. RESULTS We demonstrated that POMx exhibited potent in vitro cytotoxicity in metastatic castration-resistant PCa cells. Mechanistic studies identified survivin as a novel molecular target that may mediate the anti-cancer activity of POMx, presumably through the inhibition of signal transducer and activator of transcription 3. The in vivo administration of POMx treatment effectively inhibited survivin, induced apoptosis, retarded C4-2 tumor growth in skeleton and significantly enhanced the efficacy of docetaxel in athymic nude mice. CONCLUSION These results provide the first preclinical evidence that POMx may be effective in treating metastatic castration-resistant PCa and enhancing the efficacy of docetaxel chemotherapy. Prostate 74:497-508, 2014.

AB - Docetaxel treatment is the only first-line chemotherapy with a survival benefit in metastatic castration-resistant prostate cancer (PCa). Nonetheless, most patients become docetaxel resistant and inevitably progress with no cure. In this study, we investigated the potential of pomegranate extract (PE) in targeting metastatic castration-resistant PCa and improving docetaxel chemotherapy. METHODS The in vitro and in vivo effect of POMx, a PE formula currently approved for clinical trials, in metastatic castration-resistant PCa cells was evaluated in experimental models. RESULTS We demonstrated that POMx exhibited potent in vitro cytotoxicity in metastatic castration-resistant PCa cells. Mechanistic studies identified survivin as a novel molecular target that may mediate the anti-cancer activity of POMx, presumably through the inhibition of signal transducer and activator of transcription 3. The in vivo administration of POMx treatment effectively inhibited survivin, induced apoptosis, retarded C4-2 tumor growth in skeleton and significantly enhanced the efficacy of docetaxel in athymic nude mice. CONCLUSION These results provide the first preclinical evidence that POMx may be effective in treating metastatic castration-resistant PCa and enhancing the efficacy of docetaxel chemotherapy. Prostate 74:497-508, 2014.

KW - animal model

KW - bone metastasis

KW - docetaxel

KW - pomegranate extract

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=84894229076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894229076&partnerID=8YFLogxK

U2 - 10.1002/pros.22769

DO - 10.1002/pros.22769

M3 - Article

AN - SCOPUS:84894229076

VL - 74

SP - 497

EP - 508

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 5

ER -